Important MS Medications to Remain Subsidised for Australians
The Australian government has announced that two essential medications for Multiple Sclerosis (MS), Ocrevus and Kesimpta, will continue to be available through the Pharmaceutical Benefits Scheme (PBS). This decision ensures that patients across the country will keep receiving financial support for these high-efficacy treatments.
MS Australia has publicly welcomed the Health Minister’s announcement. The organisation highlighted that these therapies are vital for many patients, as they are often used as first-line treatments to manage the condition effectively. By keeping these drugs on the PBS, the government helps make life-changing medicine more affordable for those living with the disease.
For many Australians, the cost of specialised medication can be a significant burden. The PBS plays a crucial role in the healthcare system by subsidising the price of prescription drugs, ensuring that patients can access the care they need without facing extreme financial hardship. The decision to maintain the subsidy for Ocrevus and Kesimpta provides long-term certainty for the MS community.
This update is part of the government's ongoing commitment to supporting Australians with chronic health conditions. By continuing to fund these specific therapies, the health department aims to improve the quality of life for thousands of people currently managing MS. Patients are encouraged to speak with their doctors to discuss how this news affects their ongoing treatment plans.